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Background: Chemotherapeutic treatment of hepatocellular carcinoma often leads to chemoresistance during
therapy or upon relapse of tumors. For the development of better treatments a better understanding of
biochemical changes in the resistant tumors is needed. In this study, we focus on the characterization of in vivo
chemoresistant human hepatocellular carcinoma HUH-REISO established from a metronomically cyclophosphamide
(CPA) treated HUH7 xenograft model.
Methods: SCID mice bearing subcutaneous HUH7 tumors were treated i.p. with 75 mg/kg CPA every six days.
Tumors were evaluated by immunohistochemistry, a functional blood-flow Hoechst dye assay, and qRT-PCR for
ALDH-1, Notch-1, Notch-3, HES-1, Thy-1, Oct-4, Sox-2 and Nanog mRNA levels. Cell lines of these tumors were
analyzed by qRT-PCR and in endothelial transdifferentiation studies on matrigel.
Results: HUH-REISO cells, although slightly more sensitive against activated CPA in vitro than parental HUH-7 cells,
fully retained their in vivo CPA chemoresistance upon xenografting into SCID mice. Histochemical analysis of
HUH-REISO tumors in comparison to parental HUH-7 cells and passaged HUH-PAS cells (in vivo passaged without
chemotherapeutic pressure) revealed significant changes in host vascularization of tumors and especially in
expression of the tumor-derived human endothelial marker gene PECAM-1/CD31 in HUH-REISO. In
transdifferentiation studies with limited oxygen and metabolite diffusion, followed by a matrigel assay, only the
chemoresistant HUH-REISO cells exhibited tube formation potential and expression of human endothelial markers
ICAM-2 and PECAM-1/CD31. A comparative study on stemness and plasticity markers revealed upregulation of
Thy-1, Oct-4, Sox-2 and Nanog in resistant xenografts. Under therapeutic pressure by CPA, tumors of HUH-PAS and
HUH-REISO displayed regulations in Notch-1 and Notch-3 expression.
Conclusions: Chemoresistance of HUH-REISO was not manifested under standard in vitro but under in vivo
conditions. HUH-REISO cells showed increased pluripotent capacities and the ability of transdifferentiation to
endothelial like cells in vitro and in vivo. These cells expressed typical endothelial surface marker and functionality.
Although the mechanism behind chemoresistance of HUH-REISO and involvement of plasticity remains to be
clarified, we hypothesize that the observed Notch regulations and upregulation of stemness genes in resistant
xenografts are involved in the observed cell plasticity.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon malignancy worldwide [1]. Moreover, its incidence
increases due to hepatitis B and C viral infections. There-
fore, HCC is in the focus of several treatment studies.
Compared to other solid tumors, HCC is characterized by
high levels of vascularization. The status of angiogenesis
correlates with cancer progression and prognosis. There-
fore, antiangiogenic strategies are suggested for treatment
of HCC [2] due to survival advantages, as revealed in re-
cent studies [3,4]. In addition, the usage of preclinical
antiangiogenic, metronomic regimen of cyclophosphamide
(CPA) revealed encouraging results in terms of tumor
growth suppression and survival in an in vivo rat model of
hepatocellular carcinoma [5]. The metronomic treatment
regimen is characterized by significantly reduced side ef-
fects, compared to conventional maximum tolerated che-
motherapy administration and by antitumoral activity in
respect to its antiangiogenic properties. The metrono-
mic treatment regimes target preferentially genetic stable
tumor vessel endothelial cells and thus, the development
of resistance against the therapy should be avoided [6,7].
However, several studies point towards the induction of
in vivo chemoresistance mechanisms that let tumors es-
cape from metronomic CPA therapy [8-10].
In this study, we investigated changes in transcription
factors, controlling plasticity and stemness of tumor cells
in an in vivo chemoresistance HCC xenograft mouse
model. Resistant HCC xenografts were generated by
metronomically scheduled CPA treatment in SCID mice,
resulting in resistant tumor outgrowth after an initial
chemoresponsive phase of 10 weeks. Histological ana-
lysis revealed significant changes in tissue organization
and blood flow. Re-xenografted tumors from HUH-
REISO cell culture manifested immediate chemoresis-
tance, lacking an initial response phase. In order to
detect gene expression associated with the chemo-
resistance and its development, expression levels of
Notch-1 and downstream HES-1, Notch-3, Thy-1, Oct-4,
Sox-2 and Nanog were determined in in vivo passaged
control xenografts and in their resistant counterparts with
and without therapeutic pressure. Furthermore, several as-
pects of cell differentiation were traceable in specialized
in vitro models, mimicking features of environmental
properties of solid tumors.
Methods
Cell culture
Cell culture media, antibiotics, fetal bovine serum
(FBS) and trypsin/EDTA solution were purchased from
Invitrogen GmbH (Karlsruhe, Germany). Human hepa-
toma cells (HUH-7) (JCRB0403) were cultured in a
mixture of Ham’s-F12 and Dulbecco’s modified Eagle’s
medium (DMEM) in a ratio of 1:1 supplemented with10% FBS. Cells were grown at 37°C in 5% CO2 in a hu-
midified atmosphere. HUH-7 cells were cultured with-
out antibiotics for at least 3–4 passages before tumor
cell implantation and were harvested just as reaching
approx. 70% confluency.
In vivo animal model
Male SCID mice (CB17/lcr-PrkdcSCID/Crl) (8–10 weeks)
were housed in individually vented cages under specific
pathogen free conditions with a 12 h day/night cycle and
with food and water ad libitum. HUH-7 cells were cul-
tured as described above. The number of 106 HUH-7
cells in 100 μl PBS was injected subcutaneously with a
25 G needle (Braun, Melsungen, Germany) into the flank
of SCID mice. The animals were checked regularly for
tumor progression. The moment that tumor volume
reached the size of at least 10 mm3, tumor progression
was monitored using a digital measuring slide (Digi-Met,
Preisser, Gammertingen). Each measurement consisted
of three diameters, length (a), width (b), and height (c).
Tumor volume was calculated by the formula a × b × c ×
π/6 (with a, b and c indicating the three diameters and
π/6 as correction factor for tumor shape). Tumor
volume doubling time was calculated with TVDT =
ln2x(t2 − t1)/ln[V(t2)/V(t1)]. All animal experiments were
performed with 6 animals per group. All animal proce-
dures were approved and controlled by animal experi-
ments ethical committee of Regierung von Oberbayern,
District Government of Upper Bavaria, Germany and car-
ried out according to the guidelines of the German law of
protection of animal life.
Isolation of tumor cells
For isolation of tumor cells, mice were sacrificed at the
first therapy endpoint (see Figure 1 and Additional file 1:
Table S1) with CO2. Skin was cleaned and sanitized with
isopropanol (70% in water v/v), followed by drying under
sterile conditions. Tumors were collected and immediately
immerged in a 1:1 mixture of Ham’s-F12 and Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
10%FBS and 2% penicillin/streptomycin (Biochrom, Berlin,
Germany). Tumor tissue was reduced to small sections
under sterile conditions. Pieces were chosen randomly
from all areas of the tumor. This procedure was repeated
until the tumor tissue was homogenized. The obtained ho-
mogenized cell suspension was diluted with fresh penicil-
lin/streptomycin containing Ham’s-F12 and DMEM 1:1.
The tumor cell containing suspension was transferred to
tissue 6-well-plates (TPP, Trasadingen, Switzerland) and
incubated under standard conditions (37°C, 5% CO2) in a
humidified atmosphere for 2–3 days. Just as cells attached
to the bottom of the plate, medium was replaced every
second day, until cells reached a confluence of about
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Figure 1 In vivo chemoresistance. (A) Subcutaneous human HUH-7 tumors were established in SCID mice by injection of 5×106 HUH-7 cells
into the flanks of animals (n=6). CPA treatment was started on day 12 after tumor implantation with 75 mg/kg CPA every sixth days.
Metronomically scheduled CPA treatment resulted in significant tumor growth delay. Tumor volume of treated mice was constant up to day 75
after tumor cell implantation, whereas tumors in the control group exhibited a tumor volume doubling time of 2.5 days. Around day 75 after
tumor cell implantation tumor volume began to increase in the CPA treated group, despite ongoing treatment with a tumor doubling time of
3.5 days. (B) Cells isolated from resistant CPA treated tumors (HUH-REISO) were cultured in vitro and, after several passages, reimplanted in SCID
mice (n=6) again, with CPA therapy (75mg/kg every sixth days) starting at day 10 after cell implantation. A cell line established from in vivo
passaged tumor cells (HUH-PAS) served as control. Tumors derived from HUH-REISO cells revealed a tumor volume doubling time (under therapy)
of 4.5 days, whereas tumor growth in the control group was not evident within the observed time.
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ies were performed by injection of 106 HUH-7 tumor cells
at a passage number below 10.
Chemotherapy
Cyclophosphamide (CPA) (Sigma, Taufkirchen, Germany)
was solved in PBS (10 mg/ml) and applied intraperitone-
ally. 75 mg/kg CPA solution was administered with a 25 G
needle (Braun, Melsungen, Germany). The application of
the CPA solution was carried out every 6 days. A single
dose of each application was based on animal body weight.
Toleration of CPA treatment was monitored by regular
measurement of body weight. The vehicle group (PBS)
and the drug treatment group (CPA dissolved in PBS)
were housed separately.
HE stain of tumors
Cryosections were fixed with 4% paraformaldehyde and
stained with haematoxilin (Sigma, St. Louis, USA) for
30 min. After washing with PBS and aqua dest., sections
were incubated with eosin (1:100 in aqua dest.) (Sigma,
St. Louis, USA) for 4 min. Afterwards, sections were
washed with aqua dest., embedded with PBS and ana-
lyzed by transmission light microscopy at the Axiovert
200 microscope (Zeiss, Jena, Germany).
Immunohistochemistry
For immunohistology, tumors were embedded in tissue
freezing medium (Jung, Nussloch, Germany). They were
cut into sections of 5–10 μm thickness with a cryo-
microtome (Leica CM 3050 s, Wetzlar, Germany) at −20°C. Sections were transferred to a microscope slide,
tissue freezing medium was removed and tissue was
fixed with 4% paraformaldehyde (in PBS). Afterwards,
sections were rehydrated and washed with blocking so-
lution (PBS containing 5% FBS) prior to antibody incu-
bation. Antibodies, which were used for the stains, are
listed in Additional file 2: Table S2. All primary anti-
bodies were diluted 1:200 in blocking solution. After in-
cubation for 12 h at 4°C in humidified atmosphere,
sections were washed repeatedly with blocking solution
followed by secondary antibody staining. Secondary anti-
bodies were diluted 1:400 in blocking solution and sec-
tions were incubated for 2 h at room temperature in
humidified atmosphere. Sections were washed with
blocking solution repeatedly, before fluorescence analysis
at the Axiovert 200 microscope (Zeiss, Jena, Germany)
using appropriate filter sets.Agarose overlay method
Cells were seeded in 6-well plates 24 h before addi-
tion of the agarose overlay. Culture medium was re-
moved and replaced with 1 ml medium containing 0.6%
(w/v) agarose (Invitrogen, Carlsbad, USA). The agarose-
containing medium was obtained by stepwise dilution
of complete medium with melted agarose (5% agarose
in medium without supplementations, w/v). Before ap-
plying the agarose-containing medium to the seeded
cells, the medium was allowed to cool to 37°C. After so-
lidification, 2 ml of complete culture medium without
agarose was added to the cells.
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To avoid cell growth in a two dimensional way, cells were
seeded into an agarose gel. Therefore, cells were harvested
as soon as reaching approx. 70% confluency. The gel was
prepared by mixing low melting agarose from Cambrex
BioScience (Rockland, USA) with medium in a percentage
of 10% (w/v). After autoclaving, the gel was diluted with
medium to 1.2%. Afterwards gel and single cell suspension
were mixed and 5,000 cells in 1 ml of 0.6% gel were seeded
in a 24 well plate (TPP, Trasadingen, Switzerland). Grown
spheroids were counted after 42 days. Pictures were taken
with an Infinity 2 camera and Infinity capture software
(both: Lumenera corporation, Ottawa, Canada).
In vitro matrigel angiogenesis assay
Matrigel was purchased from BD (Franklin Lakes, USA).
The coating procedure was done as described in the BD
guidelines for thin gel layers. Matrigel was thawed over
night at 4°C. After short homogenization of the gel by
pipetting with cooled tips, 10 μl of matrigel were added
to each well of a μ-slide angiogenesis uncoated chamber
(ibidi, München, Germany). The slide was incubated for
30 minutes at 37°C and afterwards cells were seeded on
the gel layer in an amount of 50,000 cells in 50 μl of cell
culture medium per well. Cells were grown at 37°C in
5% CO2 in a humidified atmosphere and observed with
an axiovert 200 microscope (Zeiss, Jena, Germany). Pic-
tures were taken after 24 hours with an Infinity 2 camera
and Infinity capture software (both: Lumenera corpor-
ation, Ottawa, Canada). Image analysis was performed
with the analysis software from S.Core (Hoehenkirchen,
Germany).
qRT-PCR
Marker gene analysis was done by quantitative polymer-
ase chain reaction. Therefore, pairs of primer were
designed with the universal probe library of Roche and
purchased from Matabion (Martinsried, Germany). All
pairs of primer, which were used for qRT-PCR, are listed
in Additional file 3: Table S3. Total RNA of in vivo and
in vitro samples were purified by using two different
methods. For the in vitro angiogenesis assay samples,
106 cells were seeded on a thin layer of matrigel (BD,
Franklin Lakes, USA) in a six well plate. Total RNA of
cells from one well was purified by phenol-chloroform
extraction using peqGOLD TriFast kit (Peqlab, Erlangen,
Germany). Preparation of in vivo RNA-Samples was
done with a NucleoSpin RNA II kit (Macherey-Nagel,
Düren, Germany) using 30 mg of tumor tissue. 5 μg of
purified RNA were applied for cDNA production. For
each qRT-PCR 25 ng cDNA were used for amplification
and all samples were measured in duplicates. After an
activation cycle with 90°C for 10 Minutes, 45 cycles were
performed with a 10 seconds denaturation step at 95°C,30 seconds of annealing at 60°C and polymerase ex-
tension for 1 second at 72°C. The PCR runs were
performed with Light Cycler 480 (Roche, Mannheim,
Germany). For detection, the corresponding probe out
of the universal probe library (Roche, Mannheim,
Germany) was applied. Fold changes were calculated
with the ΔΔCt- method. As GAPDH and Act-B showed
stable unregulated expression status over all tested
tumor samples in initial experiments, GAPDH was used
as reference gene for measurements of Oct-4, Thy-1,
and ALDH-1 and Act-B for measurements of HES-1,
Notch-3, Notch-1, Nanog, Sox-2, PECAM-1/CD31, and
ICAM-2. The ready to use Universal Probe Library
(UPL) reference gene assays for GAPDH and ACT-B
(Roche Diagnostics, Mannheim, Germany) were applied.
In vitro CPA sensitivity
In vitro sensitivity was assayed by measuring the DNA
content of a cell population composed of 25% of CPA
activating X39 cells mixed with either HUH-wt, or
HUH-REISO cells, followed by CPA treatment. Gener-
ation of CYP2B1 transgene expressing X39 cells is de-
scribed previously [11]. In total, 1500 cells per well
were plated in 48-well plates. Twenty-four hours after
seeding, the culture medium was removed and replaced
by either 200 μl of fresh medium or by fresh cell culture
medium containing CPA at the indicated concentrations.
Treated cells and controls were incubated for 5 days in a
humidified atmosphere containing 5% CO2 at 37°C.
DNA contents were assayed after Hoechst 33258 incorp-
oration, as previously described [11]. Briefly, cells were
lysed with Millipore water followed by a freeze–thaw
cycle. Cell lysis buffer (1 mM Tris-EDTA, pH 7.4,
200 mM NaCl) containing 0.2 ng/ml Hoechst 33258 was
applied to each well, followed by another freeze–thaw
cycle. The DNA content was measured by quantifying
fluorescence with a plate reader (Tecan, Grödig, Austria)
equipped with filters for excitation at 360 nm and emis-
sion at 465 nm. Relative DNA content was calculated
using the ratio of DNA content treated /DNA content
untreated cell culture.
Statistical analysis
U-Test (Mann–Whitney) analysis was performed with
WinStat for Exel to proof statistical significance in all
cases. * stands for p≤0.05, ** for p≤0.01.
Results
HUH7 tumors under metronomic CPA therapy in vivo
Male and female SCID mice bearing subcutaneously im-
planted human HUH7 tumors were treated with metro-
nomically scheduled CPA (75 mg/kg every 6 days). CPA
treatment was started on day 12 after tumor cell im-
plantation, just as tumors reached an average volume of
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sulted in a significant tumor growth delay. The tumor vol-
ume of treated mice was constant at around 100 mm3 up
to day 75 after tumor cell implantation, whereas tumors in
the control group exhibited a tumor volume doubling
time of 2.5 days. Around day 75 after tumor cell implant-
ation, tumor volume began to increase in the CPA treated
group, with a tumor doubling time of 3.5 days, despite on-
going treatment (Figure 1A). Metronomically scheduled
CPA therapy was well tolerated, indicated by a constant
animal body weight up to day 85 after tumor cell implant-
ation (data not shown). Further CPA treatment resulted
in significant loss of body weight, observed in all CPA
treated animals (data not shown). Treatment was
stopped and the mice were sacrificed as soon as the
average body weight loss reached 20%. At this therapy
endpoint, tumors were collected and subjected to
macroscopical and histological analyses. Furthermore,
tumor cells were extracted from viable tumor tissue for
characterization and cell culture experiments. To estab-
lish appropriate control cells (HUH-PAS), HUH7 were
grown in male and female SCID mice, without exposure
to therapy. As soon as tumors reached about 300 to
400 mm3, viable cells were extracted from tumor tissue.
Reisolated cells (HUH-REISO and HUH-PAS) exhibited
the same morphology in comparison to the parental
HUH7 cells (HUH-wt) and were identified by human
EGF-Receptor staining for their human origin (Additional
file 4: Figure S1).Figure 2 Macroscopic appearance, tumor histology and functional blo
treated in vivo resistant tumor at treatment endpoint (HUH-REISO), all colle
fixed with 4% paraformaldehyde (PFA) and subjected to H/E staining (B) un
treatment endpoint (HUH-REISO). Functional blood flow was visualized by
parental tumor (HUH-wt) and (F) in vivo resistant tumor at treatment endpInfluence of CPA therapy on tumor macroscopic
appearance, tumor histology and functional blood flow
Tumors at the first therapy endpoint were macroscopic-
ally assessed. The tumor tissue appeared dark and
bloody (HUH-REISO) (Figure 2D), compared to the un-
treated control tumors (HUH-wt) (Figure 2A). For fur-
ther characterization and evaluation of changes induced
by in vivo passaging and CPA treatment, histological and
immunohistological analyses were performed. Therefore,
cryosections were stained with haematoxylin/eosin and
analyzed by transmitted light microscopy. Tissue struc-
ture in the original HUH7 xenografts (established from
HUH-wt) was compact and homogeneous (Figure 2B).
In contrast, resistant tumors (HUH-REISO) exhibited an
inhomogeneous, sponge-like structure with large cavities
within the tumor tissue (Figure 2E). These cavities were
identified as intratumoral blood lakes, due to the pres-
ence of erythrocytes. To verify this finding, in vivo
tumor blood flow was visualized by systemically applied
Hoechst 33258 dye as a tracer. Several cavities within
the tumor tissue from resistant HUH-REISO tumors
exhibited tracer fluorescence, indicating connection with
the systemic blood supply (Figure 2F). For comparison,
functional blood supply analysis was performed also for
the original xenografted HUH7 tumors (HUH-wt,
Figure 2C) and reimplanted treated HUH-PAS tumors
(Additional file 5: Figure S3 A-C). These HUH-PAS con-
trol tumors showed a clear diminished functional blood
flow.od flow. (A-C) Untreated parental tumor (HUH-wt) and (D-E) CPA
cted at day 25 after tumor cell implantation. Cryosections (8 μm) were
treated parental tumor (HUH-wt) and (E) in vivo resistant tumor at
intravenous application of Hoechst 33258 dye (blue). (C) Untreated
oint (HUH-REISO).
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xenografts
Immunohistochemical analysis of the vessel associated
markers murine PECAM-1/CD31 and laminin show-
ed an obvious shift from initial tumor vasculariza-
tion (HUH-wt) (Figure 3A), as it is typical for HUH7Figure 3 Immunohistochemical analysis for vascular markers in HUH-
(A) and CPA treated, chemoresistant tumors HUH-REISO (B) were fixed with
(green) and laminin (yellow). Significant changes in the arrangement of lam
CPA treated tumors versus control tumors. Functional blood flow was visua
Additional immunohistochemically stained cryosections of untreated HUH-
after two times CPA treatment are shown. Staining for murine CD31/PECAM
CD31/PECAM-1 (E/I/M, magenta, highlighted with white arrows) and cell n
murine CD31/PECAM-1, significant human CD31/PECAM-1 expression was
whereas human CD31/PECAM-1 expression was not detected in (C-F, HUHxenografts, to a tumor tissue with a decreased murine
vessel density (HUH-REISO) (Figure 3B) at the therapy
endpoint. Interestingly, functional blood flow, indicated
by Hoechst tracer staining, was not closely correlated
with immunohistochemically identified vessel structures
(Figure 3B).7 tumors. Cryosections (5 μm) of untreated control tumors (HUH-wt)
4% PFA and stained with antibodies for murine CD31/PECAM-1
inin and CD31/PECAM-1 positive endothelial cells were detected in
lized by intravenous application of Hoechst 33258 dye (blue).
wt (C-F) tumors, and HUH-PAS (G-J) or HUH-REISO (K-N) tumors
-1 (D/H/L, green, highlighted with black arrows) and human
uclei were counterstained with DAPI (C/G/K). Adjacent to signals from
detected in (K-N, HUH-REISO) chemoresistant, CPA treated tumors,













HUH-wt + 25% X39 HUH-REISO + 25% X39
in vitro sensitivity
Figure 4 Sensitivity of parental HUH-wt and isolated HUH-
REISO cells towards in situ activated CPA. Parental and isolated
cells were treated with different concentrations of CPA for 3 days
together with CPA activating cells X39. Proliferation was determined
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for human, besides mouse, endothelial specific marker
PECAM-1/CD31 (hPECAM-1 and mPECAM-1). Counter
stain of cell nuclei with DAPI can be seen in Figure 3C
(HUH-wt), 3G (HUH-PAS) and 3K (HUH-REISO). Con-
trol stains revealed no hPECAM-1 signal for the parental
HUH7 xenografts (Figure 3E and F), whereas mPECAM-1
(mCD31) positive cells showed a large network of vessel
(Figure 3D, highlighted with black arrows). Most interest-
ingly, Figure 3M and merged 3N showed hPECAM-1
(hCD31) positive structures (highlighted with white ar-
rows) in reimplanted resistant xenografts (HUH-REISO)
in close neighbourhood to murine vascular structures
(Figure 3L), indicating HCC plasticity towards the endo-
thelial lineage. Control tumors of HUH-PAS, which were
treated twice with CPA, showed rare positive signals
for mPECAM-1 (Figure 3H) and no positive signal for
hPECAM-1 (Figure 3I). Those HUH-PAS tumors had to
be treated late, when they had reached an average volume
of 254 mm3. At an earlier starting point of therapy of these
chemoresponsive cells there would not be enough tumor
material left for reliable analysis (Figure 1B).by measuring total DNA content per well. Control experiments were
performed in the absence of CPA. Mean values ± SD of four
measurements are shown. No significant differences were observed,
nevertheless HUH-REISO cells showed higher sensitivity.No evidence of acquired resistance in vitro
Original HUH7 cells (HUH-wt) and HUH-REISO tumor
cells were treated in an in vitro co-culture model to-
gether with X39 cells, expressing the CYP450 transgene
to convert CPA in situ into activated CPA [11]. As
shown in Figure 4, the in vivo resistant HUH-REISO as
well as the HUH-wt cells showed CPA concentration-
dependent decrease in cell proliferation, indicating no
manifestation of resistance in the in vitro setting. Inter-
estingly, the in vivo resistant HUH-REISO displayed an
insignificantly higher chemosensitivity.Resistance of reimplanted tumors towards metronomic
CPA therapy in vivo
Reisolated HUH-REISO tumor cells and reisolated in vivo
passaged (HUH-PAS) cells were implanted in the flank
of SCID mice. On day 10 after tumor cell implantation,
just as average tumor volume reached 14 mm3, mice
were subjected to CPA treatment (75mg/kg, every 6 -
days). Tumor volume and body weight were measured
regularly during the treatment. No growth retardation
effect was detectable for xenografts established from
HUH-REISO cells, in contrast to blocked growth of xe-
nografts established from in vivo passaged cells (HUH-
PAS) (Figure 1B). Resistant xenografts exhibited an
average tumor volume doubling time of approximately
4.5 days. Metronomically scheduled CPA was again well
tolerated, indicated by no significant loss in body weight
(data not shown).Regulation of ALDH-1 expression in response to CPA
therapy in vivo
As homo sapiens aldehyde dehydrogenase 1 family mem-
ber A1 (ALDH-1) is a known detoxification enzyme and
inactivates CPA intermediates, expression levels were
measured in HUH-REISO and in HUH-PAS during ther-
apy. In absence of CPA pressure, only insignificant differ-
ences in expression levels were detectable in HUH-PAS
and in HUH-REISO tumors (Figure 5). However, during
therapy, expression levels of ALDH-1 increased in both
xenograft types significantly after two treatments. In resist-
ant tumors, ALDH-1 expression levels increased 2.5-fold
after six treatments. With a p-value of 0.35, the ALDH-1
mRNA levels are not statistically different between HUH-
PAS and HUH-REISO after the 2nd treatment (2×CPA).
Expression profiles of Thy-1, Oct-4, Sox-2 and Nanog
in vivo
For characterization of stemness as a possible cause of
tumor cell plasticity, the well established stemness
markers Thy-1, Oct-4, Sox-2 and Nanog were analyzed,
after total RNA extraction from tumor tissue. Expression
analysis of untreated mice revealed that expression levels
of Thy-1 (Figure 6A), Oct-4 (Figure 6B) and Nanog
(Figure 6D) were significantly increased in resistant tu-
mors. In contrast to tumors, which were grown from
















Figure 5 Aldehyde dehydrogenase I (ALDH-1) expression levels.
Influence of CPA treatment on expression levels of ALDH-1 was
determined in tumor tissue by qRT-PCR analysis after two treatments
(HUH-PAS and HUH-REISO) and additional four treatments in the
case of HUH-REISO (n=5). CPA therapy induced ALDH-1 expression
in HUH-PAS (p=0.009) and in HUH-REISO (p=0.01) xenografts
significantly. However, the ALDH-1 level was similar for passaged
(HUH-PAS) and resistant (HUH-REISO) xenografts, independent of
therapy. Statistic evaluation was performed using the Wilcoxon-
Mann–Whitney test. P< 0.05 was considered as significant and
indicated by *, p< 0.01 was indicated by **.
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tumors, Thy-1 expression levels were about 100-fold
(p=0.014) higher, Oct-4 expression levels were about
14-fold increased (p=0.027), Sox-2 expression levels
were 5-fold (p=0.086) upregulated and expression levels
for Nanog were detected to be increased about 7-fold
(p=0.05), in comparison to tumors established from pas-
saged tumor cells (Figure 6A-D). Notably, early afterFigure 6 Expression of the plasticity markers Thy-1, Oct-4, Sox-2 and
levels of (A)Thy-1, (B) Oct-4, (C) Sox-2 and (D) Nanog was determined in tu
after two (2×CPA+; HUH-PAS, HUH-REISO) and six (6×CPA+; HUH-REISO) tre
would not survive a 6×CPA- long-term treatment in sufficient extent requir
Wilcoxon-Mann–Whitney test. P< 0.05 was considered as significant and ininitiation of CPA treatment (two times CPA therapy) ex-
pression levels of Thy-1, Oct4, Sox2 and Nanog were
found to be transiently decreased to low expression
levels, indicating transient reduction of stemness (see
discussion). Moreover, after long term treatment (6
times of CPA therapy), expression levels of all four
pluripotency markers rose in the resistant tumors again.
Expression profiles of Notch-1, Notch-3 and HES-1
Passaged (HUH-PAS) and resistant (HUH-REISO) tumor
bearing mice were treated by metronomic CPA therapy.
Interestingly, Notch-1 expression (Figure 7A) was con-
versely regulated in comparison to Thy-1, Oct-4, Sox-2
and Nanog. Significant increase of Notch-1 (about 3-fold)
expression was detected only in in vivo passaged tumors
(p=0.028) after two times of CPA treatment. Regulation of
Notch-1 in already resistant tumors was not observable.
Even after six times of chemotherapy, Notch-1 expression
levels stayed constant. However, expression of HES-1, a
target gene of the Notch pathway, was upregulated after
two CPA-treatments in passaged and in resistant tu-
mors. In HUH-PAS tumors, levels of HES-1 were 2.3 fold
higher (p=0.0090), in HUH-REISO tumors 2.4 fold higher
(p=0.0143) (Figure 7B), if compared with the correspond-
ing non-treated counterparts. After six treatments, HES-1
expression levels sank to the levels of untreated tumors.
HES-1 expression levels were about 2-fold higher in
in vivo passaged tumors, compared to in vivo resistant
tumors, independent of the treatment. Congruent to
Notch-1 regulation, significant increase of Notch-3 ex-
pression levels (about 3.7fold) were detected in in vivo
passaged tumors (p=0.0247) after two times of CPANanog in tumor tissue. Influence of CPA treatment on expression
mor tissue by qRT-PCR analysis without (CPA-) and in tumor tissue
atments (n=5 for each column). CPA-sensitive HUH-PAS tumor
ed for analysis. Statistic evaluation was performed using the
dicated by *.
Figure 7 Expression of Notch-1, Notch-3 and its downstream
target HES-1 in tumor tissue. Influence of CPA treatment on
expression levels of Notch-3, Notch-1 and its downstream target
HES-1 were determined in tumor tissue by qRT-PCR analysis before
and after two treatments (HUH-PAS and HUH-REISO) and further
four treatments in the case of HUH-REISO (n=5). (A) In contrast to
significant induction of Notch-1 expression by two CPA therapies in
passaged tumors (HUH-PAS), Notch-1 expression levels in
chemoresistant tumors (HUH-REISO) remained not significantly
altered even after further four CPA-treatments. Initial expression
levels of Notch-1 were not significantly different. (B) HES-1
expression levels were detected to be significantly induced after two
treatments for passaged (HUH-PAS) and chemoresistant tumors
(HUH-REISO). Initial expression levels and expression levels after two
CPA-treatments remained significantly low compared to tumors
grown from in vivo passaged cells (HUH-PAS). After further four
treatments, expression levels again reached initial HES-1 expression
in chemoresistant tumors (HUH-REISO). (C) Notch-3 showed in both
groups HUH-PAS (p=0.0247) and HUH-REISO (p=0.0446) significantly
upregulated levels after two times of CPA therapy. After additional
four CPA treatments, level of Notch-3 in HUH-REISO dropped back
on base levels.
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level about 2fold (p=0.0446), which appeared after two
treatments, disappeared after further four treatments.
Anchorage independent growth of HUH-wt, HUH-PAS and
HUH-REISO spheroids
For characterization of cell dependency on essential matrix
signalling, the capacity for anchorage-independent growth
was tested by their ability to form colonies in soft agar.
Multicellular spheroids were counted 42 days after embed-
ding the single cell suspension (5000 cells/well) in solid
medium. No significant differences between resistant and
non-resistant tumor cells could be observed (data not
shown), as only HUH-wt built far less spheroids than the
other two cell lines. Nevertheless, the spheroids differed in
their appearance. The parental HUH-wt cells (Figure 8A)
and in vivo passaged cells (Figure 8B) built up very com-
pact and homogeneous spheroids. In contrast, spheroids
from the resistant tumor cells (Figure 8C) were character-
ized by cavities within the spheroids. These findings could
be consolidated by HE staining of 10μm cryosections of
spheroids. HUH-wt spheroids (Figure 8D) and HUH-PAS
spheroids (Figure 8E) showed uniform and continuous
tissue without cavities, whereas HUH-REISO spheroids
(Figure 8F) presented a sponge-like structure inside the
spheroids.
Endothelial transdifferentiation in vitro
To evaluate the potential of tumor cells to transdifferentiate
into an endothelial phenotype, a tube formation assay
(Figure 9) was performed. At first, HUH-wt, HUH-PAS,
and HUH-REISO cells were pre-cultured under conven-
tional conditions (Figure 9A-C) or under a thin layer of
solid medium (“agarose overlay”, Figure 9D-F) for six
weeks. In such a diffusion controlled environment [11],
supply with nutrients and oxygen and moreover, dilution of
autocrine and paracrine factors is limited, compared to
conventional cell culture systems. After the pre-culture, the
six different cell culture groups were subjected to a conven-
tional matrigel assay (Figure 9A-F). Only HUH-REISO
cells, pre-cultured by agarose overlay, showed enough plas-
ticity to form endothelial like tubes within 4h (data not
shown). After 24h, the network was fully trained in this
group (Figure 9F), whereas HUH-wt (Figure 9D) and
HUH-PAS (Figure 9E) cells showed no striking tube forma-
tion. Moreover, tube formation was not detectable in all
three tumor cell groups pre-cultured under conventional
conditions (Figure 9A-C).
Quantification of tube formation in matrigel was
performed via software based analysis (Additional file 6:
Figure S2 and Figure 9G-J). Comparison of HUH-wt,
HUH-PAS, and HUH-REISO (all pre-cultured by agar-
ose overlay) revealed a far higher number of branching
points (Figure 9G) and tubes (Figure 9H), a very
Figure 8 Anchorage independent growth. Multicellular spheroids grew from a single cell suspension of (A) parental HUH-7 cells (HUH-wt),
(B) in vivo passaged HUH7 cells (HUH-PAS) and (C) chemoresistant cells (HUH-REISO) in low melting agarose for 42 days and pictures were taken
under a phase contrast microscop. Spheroid tissue organization was detected by H/E staining of cryoslides. (D) Parental HUH-7 cells (HUH-wt),
(E) in vivo passaged HUH7 cells (HUH-PAS) and (F) chemoresistant cells (HUH-REISO).
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amount of confluent areas without tube formation
(Figure 9J) for HUH-REISO cells.
Furthermore, expression levels of endothelial markers
(CD31/PECAM-1, ICAM-2, VEGFR2, VE-cadherin and
vWF) of agarose overlay HUH-REISO cells, showing posi-
tive tube formation, were compared to the corresponding
standard culture HUH-REISO (Figure 9K-L). Expression
levels were determined after the matrigel assay. In agarose
overlay HUH-REISO cells, ICAM-2 (p=0.009) (Figure 9K),
as well as CD31/PECAM-1 (p=0.028) (Figure 9L) were
significantly upregulated. Expression of the other endothe-
lial markers was not detectable in HUH-REISO under any
culture condition (data not shown).
Discussion
In the present study, acquired in vivo chemoresistance
against metronomic cyclophosphamide (CPA) treatment
was studied in a human hepatocellular carcinoma HUH7
xenograft mouse model. During treatment, a two phase
development of tumor progression was observable: In
the beginning of treatment (response phase), tumor pro-
gression was significantly decreased, indicated by con-
stant tumor volume for about 75 days. In the following,
second phase (escape phase), tumor volume increased
with a tumor volume doubling time of 3.5 days, des-
pite ongoing therapeutic intervention (Figure 1A). Viable
tumor cells were extracted from resistant tumors (HUH-REISO), whereas control cells (HUH-PAS) were obtained
from in vivo passaging HUH7 tumor cells without CPA
treatment. Subsequently, HUH-PAS and HUH-REISO
were characterized and identified in terms of cell morph-
ology and representative human epidermal growth fac-
tor (EGF receptor) expression for their human origin
(Additional file 4: Figure S1).
Interestingly, in vivo chemoresistant HUH-REISO did
not manifest their drug resistant phenotype in a two-
dimensional monolayer culture in presence of in situ ac-
tivated CPA (Figure 4). In addition, significant changes
in macroscopic appearance and tumor tissue organi-
zation of chemoresistant tumors indicate resistance
mechanisms, which were only gainful in the in vivo situ-
ation. However, an endogenous imprinted component
for in vivo chemoresistance was obvious, as the chemo-
resistant phenotype of isolated tumor cells was immedi-
ately manifested again after reimplantation and reapplied
chemotherapy. In the reimplantation experiment, che-
moresistance was manifested lacking the response phase.
In contrast, HUH-PAS, which were only adjusted to the
in vivo environment but not to the treatment, remained
sensitive (Figure 1B) in a response phase. The qRT-PCR
assay on in vivo samples revealed no significant differ-
ence in basal expression of the detoxification enzyme
ALDH-1 (Figure 5), which converts aldophosphamide
into carboxyphosphamide. ALDH-1 expression was de-
tected to be significant upregulated in vivo during
Figure 9 Tube formation assay. Tumor cells were seeded on matrigel after conventional cell culture (21% Oxygen / 37°C) or after a 42 days
culture in a diffusion limited environment with reduced oxygen and nutrient supply. Pictures were taken 24h after plating. (A) Parental HUH7
(HUH-wt), (B) in vivo passaged (HUH-PAS) and (C) chemoresistant (HUH-REISO) cells derived from conventional cell culture did not show tube
formation, whereas in the case of cells, derived from the diffusion limited environment, the (F) chemoresistant tumor cells (HUH-REISO) showed
significant tube formation potential in the matrigel assay, in comparison to (D) HUH-wt and (E) HUH-PAS (n=5). Software based analysis of
pictures revealed a significantly increased (G) number of branching points, (H) overall number of tubes and (I) total length skeleton in
chemoresistant cells (HUH-REISO) in comparison to both control cell lines (HUH-wt and HUH-PAS). Consequently, (J) the total confluent area was
significantly decreased for HUH-REISO (n=3). A qRT-PCR analysis, performed after the tube formation assay on the endothelial markers (K) ICAM-2
and (L) PECAM-1/CD31, revealed significantly increased expression levels for cells derived from the diffusion limited environment culture
compared to conventional cultured cells, which did not show tube forming potential (n=6).
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was not significantly different in chemosensitive and che-
moresistant tumors. The detected chemosensitivity of
HUH-PAS exclude resistance by unspecific selection pro-
cesses in vivo, which might change cellular properties in-
dependently of therapeutic pressure [12,13].
As metronomic CPA treatment is known to suppress
tumor angiogenesis [6], functional blood flow analysis was
performed, revealing blood flow in a part of the newly
formed cavities of chemoresistant tumors (Figure 2F). In
contrast to untreated animals, blood flow was not obli-
gatory colocalized with immunohistochemical detected
laminin and mouse PECAM-1/CD31 signal (Figure 3B).
Further analysis on human vessel markers revealed with-
in the tumor the presence of cells expressing human
PECAM-1/CD31 (Figure 3M/N), indicating plasticity of
the tumor cells and initiation of differentiation towards
the endothelial lineage. This differentiation was observed
only in HUH-REISO. In HUH-PAS the CPA therapy ledto a deletion of murine vessels (Figure 3H), while the
capacity of building new human vessels was not ob-
served. As HUH-REISO showed no diminished blood-flow
(Additional file 5: Figure S3) and also a supplementation of
destroyed murine vessels by human endothelial cells, re-
sistance is partly caused by a better blood-supplementation
due to the higher plasticity of HUH-REISO. Better blood-
supplementation leading to higher drug delivery into the
tumor presumably requires also other detoxification mech-
anisms for the resistance. The higher levels of ALDH-1 in
HUH-REISO (6×CPA, Figure 5) are consistent with this
hypothesis. Therefore, further changes in the microenvir-
onment and proteome of the resistant tumor cells remain
to be examined in future work.
Plasticity becomes often apparent in combination with
the capacity of self-renewal and potential of anchorage
independent growth, often assessed in spheroid building
capacity assays [14,15]. In such an assay, no significant
differences between resistant and non-resistant tumor
Figure 10 Acquired chemoresistance towards metronomic CPA
therapy – a hypothetical model of the equilibrium between
stem cells and endothelial like cells in HUH-REISO. During
therapeutic pressure tumor cells acquire stepwise pluripotency.
Reprogramming is associated with regulations of the Notch-pathway
(Notch-1), resulting in enrichment of cells with increased expression
levels of Thy-1, Oct-4, Sox-2 and Nanog. This pool of cells is the
basis for increased adaptiveness of the tumor to therapy effects as
hypoxia. Differentiation to a functional endothelial like phenotype,
connected with tissue reorganization, counteracts antiangiogenic
therapy. Finally, in the chemoresistant tumors an equilibrium
between differentiation and self-renewal exists. In contrast to
chemoresistant tumors, induction of Notch-3 expression in
chemosensitive tumors leads to the induction of a differentiation
process, which nearly flushes out the whole pool of pluripotent
tumor cells.
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spheroids derived from HUH-wt (Figure 8A/D) or from
in vivo passaged HUH-PAS cells (Figure 8B/E), spher-
oids formed from HUH-REISO cells revealed the forma-
tion of cavities and tubular structures (Figure 8C/F).
This indicated cellular changes, which differed from the
environmental conditioning of in vivo passaging. The
consequent sponge-like growth (both in spheroids and
in tumors) might also ensure an easier supplementation
of HUH-REISO tissue with nutrients and oxygen than in
compact HUH-PAS and HUH-wt tissue. Thus, for ex-
periments HUH-PAS cells were used as an adequate
control, to characterize development of chemoresistance
in vivo. Taking the detected plasticity into account,
HUH-PAS and HUH-REISO in vivo tumors were ana-
lyzed for expression profiles of markers, which are highly
expressed in embryonic cells and described in recent pa-
pers about tumor initiating cells. Expression of Oct-4
plays a crucial role in maintaining pluripotency in stem
cells [16]. Additionally, Sox-2 and Nanog expression
contribute to plasticity, self-renewal and stemness [17].
Especially, in the context of HCC tumor stem cell re-
search, Thy-1 expression is discussed as one crucial
regulator of stemness and its upregulation is described
in the context of chemoresistance [18]. In the absence of
chemotherapy (−CPA, Figure 6A-D) in vivo qRT-PCR
revealed significantly increased expression levels of Thy-1,
Oct-4, Sox-2 and Nanog in the reimplanted chemo-
resistant HUH-REISO tumors compared with the in vivo
passaged HUH-PAS control tumors. This indicates an in-
herent difference of the chemosensitive HUH-PAS and
chemoresistent HUH-REISO tumors, with an enrichment
of tumor cells with a reprogrammed, embryonic-like sta-
tus for HUH-REISO. To monitor the response of HUH-
REISO tumors towards CPA treatment with time, qRT-
PCR analyses were performed also after 2× CPA and 6×
CPA treatment. HUH-PAS tumors were analyzed in paral-
lel, but for 2 treatments only and not the late time point
(6× CPA), because of lack of tumor outgrowth on the one
hand, or upon outgrowth conversion into a REISO-type
resistant tumor on the other hand. At the earlier (2×CPA)
timepoint resistance was not yet established for HUH-PAS
(day 14, no tumor outgrowth, Figure 1B). In vivo passaging
alone generated only few cells with pluripotent capacities
(HUH-PAS, CPA-), but these cells differentiated very
fast or got lost under therapeutic pressure (HUH-PAS,
2×CPA). In contrast, HUH-REISO generate tumor tissue
containing a pluripotent subpopulation (Figure 6, -CPA).
Upon CPA treatment HUH-REISO tumors continue to
grow, but partly lost their pluripotent stem cell population
during the acute response to the first two treatments
(Figure 6, HUH-REISO, 2×CPA), presumably by differenti-
ation. Chemoresistent tumors however were able to re-
generate the pool of stem cells (Figure 6, HUH-REISO,6xCPA) and reached a “steady-state” with stemness
markers again. Based on these stemness marker results,
recent papers [19-22] and our results regarding Notch-
pathways, we propose the hypothesis shown in Figure 10.
In line with literature [19], the process of reprogramming
was connected to induction of Notch-1 expression, as a
first response to chemotherapeutic pressure (Figure 7A).
Induction of Notch-1 leads to the expression of GIMAP5
[19], which is antiapoptotic and has potential to save cells.
ALDH-1 was simultaneously induced (Figure 5) and led to
cell survival under therapeutic pressure. Furthermore,
induction of HES-1, which is a downstream target of
Notch-1, was observable (Figure 7B). HES-1 belongs to the
basic helix loop helix family of transcription factors and is
described by Kageyama et al. as a crucial factor in many
tissues to maintain the status of pluripotency [20]. Notch-1
and HES-1 were only upregulated in the response phase of
therapy, indicating an initial key factor in this process.
In the escape phase of already chemoresistant tumors,
Notch-1 was steadily regulated under chemotherapeutic
pressure, indicating that Notch-1 was essential for the
preservation of the reprogrammed status, once Thy-1,
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renewal.
Surprisingly, after two treatments with CPA, expression
levels of Thy-1, Oct-4, Sox-2 and Nanog were decreased
in HUH-REISO (Figure 6A-D), indicating a process of dif-
ferentiation, which obviously antagonize further enrich-
ment of this subpopulation at this point of treatment. This
correlated with the induction of Notch-3 expression. The
Notch-3 pathway is described as an important signalling
pathway in the development of vascularization. N. Lawson
et al. [21,22] showed the important role of Notch-3 in ar-
terial cell fate during blood vessel development. However,
after prolonged CPA treatment, expression levels of all
pluripotency markers recovered. The initial expression
profile of Notch-3 and the profile of Thy-1, Oct-4, Sox-2
and Nanog pointed to an adaptation process, as a response
to acute chemotherapeutic pressure. Obviously, differenti-
ation was repressed again after adaptation and the balance
returned to enrichment of pluripotent cells. An important
step to the in vivo chemoresistance in our model was
therefore the development of a pool of cells, which reveal
increased levels of pluripotency markers and obviously
help to overcome chemotherapeutic pressure by initiation
of differentiation (Figure 10). In contrast to chemo-
resistant tumors, the CPA therapy in chemosensitive tu-
mors led to the induction of differentiation processes and
cell death, which in the beginning of treatment nearly
flushed out the whole pool of pluripotent tumor cells. Re-
covering of this pool took long time (growth delay phase
Figure 1B) and led, beside other mechanisms, in the end
to resistance (Figure 1A).
This differentiation process, resulting in the reor-
ganization of tumor tissue, helped tumors to escape the
metronomic treatment. To investigate the trigger, which
caused differentiation, HUH-wt, HUH-PAS, and HUH-
REISO cells, were pre-cultured in an in vitro cell culture
system, which mimics several features of solid tumors
under therapeutic pressure. In a following matrigel tube
formation assay, usually performed for angiogenesis
studies [23], HUH-REISO cells showed tube forma-
tion capacity (Figure 9F), whereas cells pre-cultured
under conventional conditions showed no functionality
(Figure 9C). Importantly, HUH-wt and HUH-PAS re-
vealed no tube formation potential, independently of
pre-culture conditions. Obviously, initiation of differenti-
ation only took place in an environment, which was
characterized by limitation of oxygen supply and simul-
taneous diffusion limitation of paracrine and autocrine
factors. In recent studies, the phenomena of tumor cell
tube formation on matrigel was detected e.g. for glio-
blastoma, breast cancer [24] and multiple myeloma [25].
In several studies the feature of tube formation was in-
dependent from the expression of endothelial markers
(vascular mimicry) [26]. However, in the case of HUH-REISO cells, tube formation was associated with induc-
tion of the endothelial genes PECAM-1/CD31 and
ICAM-2 (Figure 9K/L). In contrast, other endothelial
marker genes as vWF, VEGFR2 and VE-Cadherin (data
not shown) were neither expressed, nor regulated. Ex-
pression of endothelial genes was published by Bussolati
et al. and Bruno et al., who detected induction of endo-
thelial marker expression, derived from tumor initiating
cells (tumor stem cells) by treatment via VEGF [27] or
after xenografting [28]. Apparently, HUH-REISO cells,
or at least a subpopulation acquired a reprogrammed
status characterized by enormous plasticity. This pool of
cells reacted on environmental requirements by initi-
ation of differentiation in specialized cells to maintain a
balanced tumor microenvironment, ensured sufficient
oxygen and nutrient supply and finally counteracted
metronomic therapy.
Conclusions
In conclusion, studying the escape mechanism towards
metronomically applied CPA therapy in a HCC xeno-
graft model revealed a multistep process, going beyond
unspecific enrichment of a certain subpopulation by the
in vivo tumor environment. First step of this process
was the enrichment of detoxicating enzyme ALDH-1 in
combination with upregulation of the Notch1-pathway
and its protective downstream effector proteins. Second
step was a selection process of pluripotent, stem cell
marker expressing cells. These cells increased endothe-
lial transdifferentiation in vivo and in vitro. Functionality
of such endothelial-like cells helped resistant tumors to
overcome anti-angiogenic therapy and was the most im-
portant finding of our study. Further examinations how
modification of Notch signalling may impact cell plasti-
city and differentiation remain to be explored in future.
Additional files
Additional file 1: Table S1. Abbreviations of cell lines and their origin.
Additional file 2: Table S2. Used antibodies for immunohistochemistry.
Additional file 3: Table S3. Used pairs of primer for qRT-PCR.
Additional file 4: Figure S1. In vitro control of new generated cell
lines. HUH-wt (A), HUH-PAS (B) and HUH-REISO (C) showed no
differences in morphology by transmitted light microscopy. Moreover, in
FACS analysis cells showed human origin as all cells of HUH-wt (D),
HUH-PAS (E) and HUH-REISO (F) were positive in the staining for human
epidermal growth factor receptor (hEGF-R), indicated by the shifted red
curve in comparison to the correspondent control antibody (white
curve).
Additional file 5: Figure S3. Hoechst-blood-flow comparison of HUH-
REISO vs HUH-PAS after therapy. Intratumoral functional blood flow was
visualized by intravenous application of Hoechst 33258 dye (blue).
Cryosections (5μm) of HUH-PAS control tumors after 2×CPA treatment
(A-C) showed a clear diminished functional blood flow in comparison to
treated HUH-REISO tumors (D-F). To ensure to have tumor-material for
analysis, the beginning of treatment was late for HUH-PAS tumors, when
tumors reached an average volume of 254 mm3.
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http://www.biomedcentral.com/1471-2407/13/176Additional file 6: Figure S2. Software based analysis of Matrigel assay.
The software based analysis system projected a mask on pictures from
transmitted light microscopy of matrigel assay (same pictures as
described in Figure 9D, E and F). In white are confluent areas, in blue are
nodular structures coloured and built counted tubes with orange and
red coloured areas. The tube skeleton is indicated in the thin white lines
and their crossing points are defined as branching points. As HUH-wt (A)
and HUH-PAS (B) revealed no tube formation, the projected mask is
hardly coloured (D and E). HUH-REISO (C) showed low amount of
confluent white area and accordingly contained all other aspects of
functional tube formation in the mask (F).
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